Spexis AG
Develops therapeutics for rare diseases, oncology, and antimicrobial resistance.
SPEX | SW
Overview
Corporate Details
- ISIN(s):
- CH0106213793
- LEI:
- 391200S8HJE1I96FIG04
- Country:
- Switzerland
- Address:
- Hegenheimermattweg 125, 4123 Allschwil
- Website:
- https://www.polyphor.com/
- Sector:
- Manufacturing
Description
Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2017-04-20 13:33 |
Polyphor announces two oral and six poster presentations plus a press conferenc…
|
English | 8.3 KB | ||
| 2017-04-12 09:00 |
Polyphor AG: Polyphor announces closing of CHF 40 million private financing rou…
|
English | 6.5 KB | ||
| 2017-03-06 12:00 |
Polyphor AG: Debra Barker Appointed New CMDO of Polyphor
|
English | 7.1 KB | ||
| 2017-02-09 09:00 |
Polyphor AG: Polyphor Receives CHF 2.3 Million Award from Wellcome Trust to Acc…
|
English | 8.5 KB | ||
| 2016-12-12 09:11 |
Polyphor AG: Polyphor achieves milestone in Taisho collaboration
|
English | 4.6 KB | ||
| 2016-12-07 16:00 |
Polyphor AG: Polyphor achieves milestone and extends R&D collaboration
|
English | 4.8 KB | ||
| 2016-10-18 14:07 |
Polyphor AG: Giacomo Di Nepi Appointed New CEO
|
English | 6.0 KB | ||
| 2016-08-10 09:01 |
Polyphor AG: Polyphor and Gilead establish R&D macrocycle drug discovery collab…
|
English | 5.0 KB | ||
| 2016-06-06 08:50 |
Polyphor AG: Polyphor successfully completes clinical Phase I study with POL601…
|
English | 7.0 KB | ||
| 2016-03-23 14:11 |
Polyphor AG: Polyphor announces $3 Million Award from Cystic Fibrosis Foundatio…
|
English | 7.0 KB | ||
| 2015-12-22 09:13 |
Polyphor and Boehringer Ingelheim extend macrocycle R&D collaboration
|
English | 5.3 KB | ||
| 2015-12-01 09:20 |
Polyphor announces extension of R&D collaboration
|
English | 5.3 KB | ||
| 2015-09-17 08:59 |
Polyphor and Taisho enter into research collaboration on novel drug candidates
|
English | 4.6 KB | ||
| 2015-09-01 09:00 |
Polyphor extends clinical development portfolio by advancing its inhaled elasta…
|
English | 7.2 KB |
Automate Your Workflow. Get a real-time feed of all Spexis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Spexis AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Spexis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-21 | N/A | Executive member | Other | None | N/A |
Peer Companies
